Abstract
In the phase II VISION study, tepotinib demonstrated durable efficacy in patients (pts) with NSCLC harboring METex14 skipping. Here, we report updated efficacy outcomes (cut-off: July 1, 2020), including analyses by prior therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
